HeraMED Enters UK through Launch of B2C Website

HeraMED Limited (ASX: HMD) is an innovative medical technology company. It is into providing pregnancy monitoring solutions for home and professional use. The company cooperates with expecting parents, offer solutions related to problems associated with the reliability of pre-natal analysis.

The company today, on 11th April 2019, announced that it had made an entry in the United Kingdom after the launch of its dedicated business to consumer website (www.herabeat.co.uk). The launch was greeted with positive feedback from senior medical executives, hospitals and consumers in the United Kingdom and Israel.

By expanding into the United Kingdom market, the company is able to find its way to the largest addressable market that HeraMED currently has exposure to. The United Kingdom has ~770,000 births per annum, and hence an entry in such a huge market will also ensure a strong foundation for growth throughout Europe.

The company is decisive about the progress in the United Kingdom expansion initiatives after it has received positive feedback from discussions with a range of senior obstetricians and gynaecologists at both private hospitals and medical institutions that are part of the UK’s National Health Service. It has undertaken several meetings and product trials within the medical community in the United Kingdom and is confident of endorsement of the product and its potential success in the region.

Further, the company was successful in establishing a qualified logistics partner, as well as a digital marketing agency for enhancing growth during an initial soft launch phase. It will advance discussions with medical institutions, private hospitals and government organisations to progress its ‘top-down’ strategy throughout the United Kingdom and Europe more broadly. The company will aim to establish a pilot trial with a hospital in the UK and pursue agreements with distribution partners in the region.

HeraMED expects to update the shareholders accordingly with these developments as it materialises. The company is confident that its strategy and product offering have the support necessary to progress with the international expansion after it has received testimonials from consumers in Israel and the broader medical community. HeraMED believes that it has built and refined a cost-effective marketing and branding strategy, which can be used in other countries without much change.

The CEO and Co-founder of the company, Mr. David Groberman said that the entry in the United Kingdom is a triumph for the company since the region represents the largest addressable market of the company till now, and it also provides the company with several potential growth opportunities via private hospitals and other medical organisations.

The company has received positive feedback about the HeraBEAT device from consumers, doctors and medical institutions, although it is in the preliminary stage. This gives the company an opportunity to be well placed ahead of scale up and broader commercialisation across the region. Moreover, the company’s discussions are in progress with several parties for its expansion globally.

On the stock performance front, the stock of HeraMED is currently trading at $0.235, with a market capitalisation of $20.57 million (on 11th April 2019 AEST 02:26 PM). It has generated a YTD return of 34.29% and has an average trading volume of 153,253.


Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.

Top 25 Dividend Stocks report for April

People prefer a dividend stock in their portfolio as it possesses the feature of compounding. Compounding means that the earning which is generated through these dividend stock will get reinvested and will eventually create earnings from earning. More precisely, the dividend generated from these dividend stock will get reinvested to buy another set of a share of the dividend stock which results in giving a higher dividend.

Click here to download your top 25 dividend stocks report!

6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report